Bioequivalence Study of Gabapentin 400 mg Capsules Under Fasting Conditions
Status:
Completed
Trial end date:
2002-12-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to compare the single-dose relative bioavailability of
Ranbaxy and Parke-Davis (Neurontin®) 400 mg Gabapentin, following administration of a 400 mg
dose under fasting conditions